Biogen Idec Inc http://www.alacrastore.com/company-snapshot/Biogen_Idec_Inc-1030784 Saturday, July 26, 2008 1:34:06 PM 1030784 Biogen Idec Inc en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/B1895428ccbn/B1895428norm...BIIB saw an acceleration of TYSABRI patient adds as physicians grow more comfortable with the safety profile.... 7/22/2008 9:05:43 PMBiogen Idec Inc.106.0000EditedQ2 2008 Biogen Idec Inc. Earnings Conference Call SummaryBIIB8:30am ETBriefB1895428Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1895428ccbn/T1895428norm...Good morning. My name is Kristen and I will be your conference operator today. At this time, I would like to welcome everyone to the Q# Biogen Idec earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (OPERATOR INSTRUCTIONS) Thank you. Ms. Woo, you may begin your conference. ... 7/22/2008 11:05:42 AMBiogen Idec Inc.106.0000FinalQ2 2008 Biogen Idec Inc. Earnings Conference Call TranscriptBIIB8:30am ETTranscriptT1895428Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-26486749newstex/BW-0001-26486749xml Jul. #, #### (Business Wire) -- Biogen Idec Inc. (NASDAQ: BIIB) today announced it will report second quarter #### financial results on Tuesday, July ##, #### before the financial markets open. Following the release of the financials,...040000000401600004016048040160187/7/2008 1:18:00 PM180000001800800018004000Business WireBW-0001-26486749BIOGEN IDEC INCBIIBNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26056102newstex/PRN-0005-26056102xml SEATTLE, Jun. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) announced today an agreement with Bayer Schering Pharma to gain access to Bayer's phase III Zevalin(R) ([##Y]-ibritumomab...070000000700500007013000150000001503100004000000040020000400200604006000040060050401600004016005040100000401000107014000070140080700100007001004020000000200200002002004020020056/18/2008 2:15:25 AM180000001801600019000000190010001900200019002007PR Newswire USPRN-0005-26056102BIOGEN IDEC INCCELL THERAPEUTICS INCJAMES A BIANCOBIIBCTICNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-25038483newstex/BW-0001-25038483xml SAN DIEGO, May #, #### (Business Wire) -- Apoptos Inc., an oncology research and development company, today announced that it has secured $## million in funding. Major investors in the milestone-driven, two-tranche Series A financing...07000000070050000400000004017000090000000901500007001000070010040700100707014000070140080401600004016008040060000400600513000000130020001300200513010000130100051300500013005002110000001100600011006003110060085/6/2008 9:37:34 AM1800000018007000Business WireBW-0001-25038483BIOGEN IDEC INCWILLIAM H RASTETTERBIIBNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-24949481newstex/BW-0001-24949481xml WALTHAM, Mass., May #, #### (Business Wire) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial...070000000700500004000000040160000401600104016018040160470401600304002000040020060701400007014012070140085/1/2008 5:16:41 PM180000001800400018012000190000001900100019001014Business WireBW-0001-24949481BIOGEN IDEC INCGENENTECH INCIMMUNOGEN INCSANOFI-AVENTISMITCHEL NULL SAYAREBIIBDNAIMGNSNYNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1813667ccbn/B1813667norm...Saw an acceleration of TYSABRI patient adds, as physicians grow more comfortable with safety profile. ... 4/23/2008 1:06:00 PMBiogen Idec Inc.54.0000EditedQ1 2008 Biogen Idec Inc. Earnings Conference Call SummaryBIIB8:30am ETBriefB1813667Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1813667ccbn/T1813667norm...Good morning; my name is Janice and I will be your conference operator today. At this time I would like to welcome everyone to the Biogen Idec first-quarter conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be and question-and-answer session. (OPERATOR INSTRUCTIONS). Ms. Woo, you may begin your conference.... 4/23/2008 12:09:00 PMBiogen Idec Inc.54.0000FinalQ1 2008 Biogen Idec Inc. Earnings Conference Call TranscriptBIIB8:30am ETTranscriptT1813667Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-24714907newstex/BW-0001-24714907xml CAMBRIDGE, Mass., Apr. ##, #### (Business Wire) -- Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today reported its first...0900000009015000070000000700500004000000040160000401600304016018040160020401600504016001040160080401605204016009040020000400200602000000020020000200200607014000070140064/23/2008 8:16:17 AM18000000180040001801600018020000180120001800600018011000190000001900100019001021Business WireBW-0001-24714907BIOGEN IDEC INCJAMES C MULLENLYNN NULL SCHENKBIIBNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-24680276newstex/BW-0001-24680276xml WOBURN, Mass., Apr. ##, #### (Business Wire) -- Cambria Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that it has closed a $#.# million Series A financing. Participating investors included Biogen...090000000901500004000000040020000400200604016000040160080700000007014000070140120701401907003000070030011300000013010000130100054/22/2008 9:19:47 AM1800000018007000Business WireBW-0001-24680276BIOGEN IDEC INCBIIBNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-24573700newstex/BW-0001-24573700xml CAMBRIDGE, Mass., Apr. ##, #### (Business Wire) -- The Board of Directors of Biogen Idec (NASDAQ: BIIB) today announced its nominees for election at the #### Annual Meeting of shareholders. The Board of Directors has nominated Cecil...09000000090150000400000004016000040160020401600804016047040160050400600004006005110000001100600011006008110060031300000013010000130100054/17/2008 10:16:40 AM1800000018012000180070001801600019000000190010001900102119001005Business WireBW-0001-24573700BIOGEN IDEC INCCECIL B PICKETTLYNN NULL SCHENKBIIBNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-24182689newstex/BW-0001-24182689xml CAMBRIDGE, Mass., Apr. #, #### (Business Wire) -- Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report first quarter #### financial results on Wednesday, April ##, #### before the financial markets open. Following the release...04000000040160000401604804016018180000001800800018004000Business Wire4/1/2008 3:26:27 PMBW-0001-24182689BIOGEN IDEC INCBIIBNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1799899ccbn/T1799899norm... - Biogen Idec - CEOThere's a great warning up here which probably more politicians need to read. It says, "Beware. Microphones are live at all times." Questions and answers. This is webcast as well so bear with me because I'll be paraphrasing and repeating questions again. I know that can be a little annoying for you guys in the audience but I want people on the webcast to be able to hear the question. ... 3/18/2008 9:05:00 PMBiogen Idec Inc.54.0000FinalBiogen Idec Inc. at Cowen and Company Health Care Conference Breakout Session TranscriptBIIB11:40am ETTranscriptT1799899Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1779937ccbn/T1779937norm... - Cowen and Company - AnalystMy name is Eric Schmidt. I'm a member of the Cowen Biotech Research Team. It's my pleasure to welcome everyone again back to the Cowen and Company ##th Annual Healthcare Conference and a special welcome to Biogen Idec who I think has participated in a great majority of these conference historically. Today we're delighted to have with us the Company's Chief Executive Officer, Jim Mullen. I see we also have Paul Clancy, the Company's Chief Financial Officer; Elizabeth Woo, Vice President, Investor Relations; and Eric Hoffman, Director of Investor Relations. So we have the whole Biotech -- the whole Cowen -- excuse me, the whole Biogen team here. And Jim says he should have some time to take your questions both in this room and if we run over, upstairs in conference room Provincetown, we'll be hosting a further breakout session. So, Jim, please? ... 3/18/2008 6:05:00 PMBiogen Idec Inc.54.0000FinalBiogen Idec Inc. at Cowen and Company Health Care Conference TranscriptBIIB11:00am ETTranscriptT1779937Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/moodys/PR_138480_396800moodys/PR_138480_396800htmlMoody's rates Biogen Idec's notes Baa#; stable outlookRating Action2/27/2008 12:37:55 AMBiogen Idec Inc.396800150.0000NewshtmlBiogen Idec Inc.PR_138480_396800Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/spcred/632512spcred/632512normThe latest News from S&P2/26/2008 1:01:15 PMNews100global632512United StatesBiotechnologyUnited StatesGlobal IssuersCorporationsConsumer ProductsHealth CareNewsNEW YORK (Standard&Poor's) Feb. 26, 2008--Standard&Poor's Ratings Services said today it assigned its 'BBB' senior unsecured debt rating to Biogen Idec Inc.'s offering of $1.0 billion in debt, to be issued in two tranches maturing in 2013 and 2018. The company will use proceeds of the debt offering to refinance existing debt. At the same time, Standard&Poor's affirmed all other ratings on Biogen Idec. The outlook is stable. "The ratings on Biogen Idec reflect the company's leading positions in the treatment of cancer and multiple sclerosis, its strong financial profile, and its conservative financial policies," said Standard&Poor's credit analyst Arthur Wong. "These factors are offset partially by the company's high revenue dependenceUSA44937009062X09065B35201010 352010 3520 35Biogen Idec Inc.361345USAIDPHNEWSGLOBISSCORPConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/632513spcred/632513normThe latest Research Update from S&P2/26/2008 1:01:15 PMResearch Update175global632513United StatesBiotechnologyUnited StatesGlobal IssuersCorporationsConsumer ProductsHealth CareResearch UpdateOn Feb. 26, 2008, Standard&Poor's Ratings Services assigned its 'BBB' senior unsecured debt rating to Biogen Idec Inc.'s offering of $1.0 billion in debt, to be issued in two tranches maturing in 2013 and 2018. The company will use proceeds of the debt offering to refinance existing debt. At the same time, Standard&Poor's affirmed all other ratings on Biogen Idec. The outlook is stable. The ratings on Cambridge, Mass.-based Biogen Idec reflect the biopharmaceutical company's leading positions in the treatment of cancer and multiple sclerosis (MS), its strong financial profile, and its conservative financial policies. These factors are offset partially by the company's high revenue dependence on a limited number of drugs. Biogen Idec is theUSA44937009062X09065B35201010 352010 3520 35Biogen Idec Inc.361345USAIDPHRESUPDGLOBISSCORPConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/moodys/COP_396800moodys/COP_396800htmlBiogen Idec Inc.Credit Opinion2/26/2008 12:13:46 PMBiogen Idec Inc.396800150.0000NewshtmlBiogen Idec Inc.COP_396800Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/ccbn/T1756118ccbn/T1756118normBiogen Idec Inc. at Merrill Lynch ##th Global Pharmaceutical, Biotechnology & Medical Device Conference2/7/2008 7:06:00 PMBiogen Idec Inc.54.0000FinalBiogen Idec Inc. at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference TranscriptBIIB1:40pm ETTranscriptT1756118Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/B1743107ccbn/B1743107normQ# #### Biogen Idec Inc. Earnings Conference Call2/6/2008 2:07:00 PMBiogen Idec Inc.54.0000EditedQ4 2007 Biogen Idec Inc. Earnings Conference Call SummaryBIIB8:30am ETBriefB1743107Credit & Investment ResearchThomson Street Events